Serum homocysteine level and eye involvement in Egyptian patients with Behçet’s disease  by Allam, Ahmed et al.
The Egyptian Rheumatologist (2014) 36, 29–34Egyptian Society for Joint Diseases and Arthritis
The Egyptian Rheumatologist
www.rheumatology.eg.net
www.sciencedirect.comORIGINAL ARTICLESerum homocysteine level and eye involvement
in Egyptian patients with Behc¸et’s disease* Corresponding author. Address: Department of Rheumatology and
Rehabilitation, Faculty of Medicine, Sohag University, 2 Mohamed
Dia-Aldin Street, Alzahraa District, Sohag, Egypt. Tel.: +20
932329694.
E-mail address: abdullahradwan@yahoo.com (A. Radwan).
Peer review under responsibility of Egyptian Society for Joint Diseases
and Arthritis.
Production and hosting by Elsevier
1110-1164  2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society for Joint Diseases and Arthritis.
http://dx.doi.org/10.1016/j.ejr.2013.09.002Open access under CC BY-NC-ND license.Ahmed Allam a, Hatem Ammar b, Abdullah Radwan c,*a Department of Clinical Pathology, Faculty of Medicine, Sohag University, Egypt
b Department of Ophthalmology, Faculty of Medicine, Sohag University, Egypt
c Department of Rheumatology and Rehabilitation, Faculty of Medicine, Sohag University, EgyptReceived 13 September 2013; accepted 19 September 2013
Available online 29 October 2013KEYWORDS
Behc¸et’s disease;
Homocysteine;
Eye involvementAbstract Aim of the work: To investigate the possible role of serum homocysteine in the eye
involvement in Egyptian patients with Behc¸et’s disease (BD).
Patients and methods: A case–control study was made on 27 patients with BD (17 males and 10
females with a mean age of 32.11 ± 7.16 years) and 19 healthy control subjects. All patients fulﬁlled
the criteria of the International Study Group for BD. The patients were categorized as BD with eye
involvement (n= 12), or BD without eye involvement (n= 15). Serum homocysteine and
C-reactive protein levels were studied in all patients and controls.
Results: The mean serum homocysteine concentrations were signiﬁcantly higher in BD patients
than in healthy controls (15.56 ± 3.52 and 7.32 ± 1.38 lmol/L, respectively; P< 0.001). Also, the
mean serum homocysteine concentrations were signiﬁcantly higher in BD patients with eye involve-
ment compared to those without eye involvement (18.50 ± 3 and 13.2 ± 1.61 lmol/L, respectively;
P< 0.001). CRP, as a marker of disease activity was signiﬁcantly higher in BD patients than in
controls (14.33 ± 8.28 and 3.21 ± 1.72 mg/L, respectively; P< 0.001), however, no signiﬁcant dif-
ference (P= 0.213) in CRP levels was found between BD patients with or without eye involvement.
Conclusion: Homocysteine may play a role in BD patients with ocular involvement. Assessment
of homocysteine may be important in the investigation and management of patients with BD, espe-
cially with ocular disease.
 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society for Joint Diseases and
Arthritis.Open access under CC BY-NC-ND license.1. Introduction
Behc¸et’s disease (BD) is a systemic disorder associated with
characteristic vasculitis that can involve veins and arteries of
all sizes [1]. Mucocutaneous, ocular, genital, articular, vascu-
lar, central nervous system and gastrointestinal involvements
may occur during the course of BD. Thrombophlebitis, deep
vein thrombosis, arterial obstruction, and aneurysms are the
more frequent vascular damages in BD [2]. Ocular involvement
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iphlebitis, periarteritis, vascular occlusion, and thrombosis,
which may lead to blindness despite intensive treatment [4].
The central feature of the histopathology of BD is an obliter-
ative and necrotizing vasculitis that affects both the arteries
and veins [5].
Homocysteine, derived from methionine, is a sulfur
containing essential amino acid. Hyperhomocysteinemia may
occur in the course of diabetes mellitus, hyperlipidemia, end
stage renal failure, psoriasis and inﬂammatory bowel disease
[6]. It may also occur due to vitamin B12 or folate deﬁciency
[7] or secondary to treatment with some drugs, such as meth-
otrexate (MTX) [8]. It is not only an independent risk factor
for atherosclerosis but is also a causative risk factor for vascu-
lar disease and thrombosis [9]. As vitamin B6, vitamin B12,
and folic acid can decrease homocysteine levels, treatment with
these vitamins can be considered to reduce the risk of venous
and arterial thrombosis [10].
There are controversial reports about the role of hyperhom-
ocysteinemia in the eye involvement of BD. Multiple studies
have shown that elevated homocysteine levels may be associ-
ated with ophthalmic vascular disease [11–17]. On the other
hand, Calikoglu et al. found that homocysteine levels were
not elevated in BD [18]. Korkmaz et al. found no association
between homocysteine level and vascular involvement [19].
The present study was performed to investigate the possible
role of serum homocysteine in the eye involvement in Egyptian
patients with BD.2. Patients and methods
This case–control study was conducted on BD patients attend-
ing the outpatient clinics of Ophthalmology and Rheumatology
andRehabilitation Departments, SohagUniversity Hospital, in
the period between April 2012 and April 2013. Twenty-seven
BD patients (17 men and 10 women; mean age
32.11 ± 7.16 years), fulﬁlling the criteria of the International
Study Group for Behc¸et’s Disease [20], and 19 matched healthy
controls (11 men and 8 women; mean age 32.05 ± 7.69 years)
were enrolled in this study. The exclusion criteria for these pa-
tients were: malnutrition or body mass index (BMI) less than
19, diabetes mellitus, hyperlipidemia, end stage renal failure,
chronic hepatitis, cardiovascular diseases, thyroid dysfunction,
cancers, psoriasis, inﬂammatory bowel disease and other
rheumatic diseases, and those taking methotrexate as well as
pregnant and lactating women. Routine history taking and
physical examination were performed. All the patients were
evaluated by an experienced ophthalmologist for the presence
of ocular involvement using the criteria of the International
StudyGroup [20]. All the patients were informed about the aims
of the study and written consents were obtained from them.
The study was approved by the local ethics committee of
Sohag-University Scientiﬁc Review Board.
2.1. Determination of homocysteine levels
Venous blood samples were collected from every subject by
sterile veni-puncture on the same day of history taking and
clinical examination. Separated serum was kept frozen at
70 C till the time of estimation of serum homocysteine.
Serum homocysteine levels were determined by the ARCHI-TECT Homocysteine assay. It is a one-step immunoassay for
the quantitative determination of total L-homocysteine in
human serum or plasma using chemiluminescent microparticle
immunoassay (CMIA) technology, with ﬂexible assay proto-
cols, referred to as Chemiﬂex. Bound or dimerised homocyste-
ine (oxidized form) is reduced by dithiothreitol (DTT) to free
homocysteine, which is then converted to S-adenosyl homo-
cysteine (SAH) by the action of the recombinant enzyme
S-adenosyl homocysteine hydrolase (rSAHHase) in the pres-
ence of excess adenosine. The SAH then competes with acrid-
inium-labeled S-adenosyl cysteine for particle-bound
monoclonal antibody. Following a wash stage and magnetic
separation, pre-trigger and trigger solutions are added to the
reaction mixture and the resulting chemiluminescence is
measured as relative light units (RLUs). An indirect relation-
ship exists between the amount of homocysteine in the sample
and the RLUs detected by the ARCHITECT i System optics.
The homocysteine concentrations were expressed as lmol/L.
2.2. Determination of C-reactive protein (CRP) levels
Serum CRP concentrations were determined by immuno-
nephelometry methods on Turbox nephelometer (Orion
diagnostica, Finland). The concentrations were expressed as
mg/L. Concentrations P6 mg/L were considered positive for
CRP.
The patients were then categorized according to the pres-
ence or absence of eye involvement. The eye involvement
group included those with uveitis, retinal vasculitis, optic atro-
phy, retinitis, retinal hemorrhage, episcleritis, papilledema,
and macular damage.
Statistical analysis: The results were analyzed by IBM-
SPSS (version 19). Results were given as means and standard
deviation. Mann–Whitney test for continuous variables was
used to examine the signiﬁcance of differences between BD
and control groups. The correlations between serum homocys-
teine levels and age, disease duration and CRP levels were ana-
lyzed by Spearman correlation analyses. P-values less than
0.05 were considered statistically signiﬁcant.3. Results
The cumulative clinical characteristics of BD patients are
shown in Table 1.
Twelve patients with BD (44.4%) had eye involvement. The
results of ophthalmologic examination are shown in Table 2.
Mean serum homocysteine concentrations in total BD
patients (15.56 ± 3.52 lmol/L) were signiﬁcantly higher
(P< 0.001) than in the healthy controls (7.32 ± 1.38 lmol/
L). Similarly, mean serum CRP levels were signiﬁcantly higher
(P< 0.001) in total BD patients (14.33 ± 8.28 mg/L) com-
pared to healthy controls (3.21 ± 1.72 mg/L). Age was not sig-
niﬁcantly different between total BD patients and healthy
controls (Table 3).
Mean serum homocysteine concentrations were
signiﬁcantly higher (P< 0.001) in BD patients with eye
involvement (18.50 ± 3.00 lmol/L) compared to those with-
out eye involvement (13.20 ± 1.61 lmol/L). Age, disease
duration and CRP levels were not signiﬁcantly different
between BD patients with and without eye involvement
(Table 4).
Table 1 Clinical characteristics of Behc¸et’s disease patients (n= 27).
Characteristics Number (%) Homocysteine level (lmol/L)
Oral ulceration 27 (100) 15.56 ± 3.52
Genital ulceration 22 (81.5) 14.77 ± 3.09
Skin lesions 21 (77.8) 14.86 ± 3.14
Positive pathergy test 13 (48.1) 15.96 ± 3.59
Joint involvement 6 (22.2) 16.33 ± 3.98
Eye involvement 12 (44.4) 18.50 ± 3.00
Vascular involvement 11 (40.7) 17.91 ± 3.86
CNS involvement 3 (11.1) 19.67 ± 2.08
Table 2 Ophthalmologic characteristics of the Behc¸et’s dis-
ease patients with eye involvement (N= 12).
Characteristics Number Homocysteine level (lmol/L)
Retinal vasculitis 4 19.75 ± 3.59
Anterior uveitis 4 17.25 ± 2.99
Panuveitis 3 19.33 ± 2.52
Optic atrophy 2 16.5 ± 0.71
Posterior uveitis 6 18.17 ± 3.76
Retinitis 1 18.04 ± 0.00
Cataract 2 18 ± 1.41
Retinal hemorrhage 3 19.67 ± 4.73
Episcleritis 1 16.32 ± 0.00
Cystoid macular edema 1 17.11 ± 0.00
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signiﬁcantly higher (P< 0.001) in patients without eye
involvement (13.20 ± 1.61 lmol/L) compared to healthy con-
trols (7.32 ± 1.38 lmol/L).
No sex difference in demographic characteristics, homocys-
teine and CRP levels was found either in total BD patients or
BD patients with or without eye involvement (Table 5).Table 3 Comparison of demographic characteristics, homocysteine
controls.
Mean ± SD Behc¸et’s disease (n= 27)
Male/female 17/10
Age (years) 32.11 ± 7.16
Disease duration (years) 4.98 ± 2.76
Homocysteine (lmol/L) 15.56 ± 3.52
C-reactive protein (mg/L) 14.33 ± 8.28
a Highly signiﬁcant difference.
Table 4 Comparison of demographic characteristics, homocystein
patients with and without eye involvement.
Characteristic BD with eye involvement (n= 12)
Male/female 8/4
Age (years) 30.67 ± 8
Disease duration (years) 4.83 ± 2.86
Homocysteine (lmol/L) 18.5 ± 3
C-reactive protein (mg/L) 16.58 ± 8.43
a Highly signiﬁcant difference.Serum homocysteine levels were not signiﬁcantly correlated
(P> 0.05) with age, disease duration or CRP levels in all
groups of BD patients (Table 6).
4. Discussion
Behc¸et’s disease (BD) is a chronic, multisystemic disease of
unknown etiology in which eye involvement is the most com-
mon cause of morbidity [21]. Since there is no available diag-
nostic laboratory test, the clinical diagnosis of BD is based
on several signs. Uveitis is one of the major criteria established
by the International Study Group for BD [20]. In this study,
eye involvement was detected in 44.4% of BD patients. In
other studies, the frequency of ocular involvement ranges
between 39% and 75% [22–26], and is characterized by
repeated, explosive ocular inﬂammatory attacks that heal
spontaneously. Between attacks there is little or no evidence
of inﬂammation in the eye. The anterior segment disease is
usually accompanied by recurrent retinal vaso-occlusive
disease, which is sight-threatening with repeated attacks.
Complications of the chronic inﬂammation include retinal
and optic atrophy, vitreous hemorrhage, neovascular glau-
coma and retinal detachment. Despite therapeutic interven-and C-reactive protein levels between BD patients and healthy
Healthy controls (n= 19) P value
11/8 –
32.05 ± 7.69 0.90
– –
7.32 ± 1.38 <0.001a
3.21 ± 1.72 <0.001a
e and C-reactive protein levels between Behc¸et’s disease (BD)
BD without eye involvement (n= 15) P value
9/6 –
33.27 ± 6.45 0.19
5.13 ± 2.67 0.66
13.2 ± 1.61 <0.001a
12.53 ± 7.98 0.09
Table 5 Comparison of demographic characteristics, homocysteine and C-reactive protein levels between male and female patients
with BD in different groups.
Characteristic Total BD patients (n= 27) BD with eye involvement (n= 12) BD without eye involvement (n= 15)
Males (17) Females (10) Males (8) Females (4) Males (9) Females (6)
Age (years) 34.18 ± 7.69 28.6 ± 4.6 32.5 ± 9.01 27 ± 4.32 35.67 ± 6.48 29.67 ± 4.84
Disease duration (years) 5.35 ± 2.96 4.4 ± 2.22 5.5 ± 3.25 3.5 ± 1.29 5.22 ± 2.86 5 ± 2.61
Homocysteine (lmol/L) 15.53 ± 3.9 15.6 ± 4.35 17.88 ± 2.7 19.75 ± 3.59 13.44 ± 1.51 12.83 ± 1.84
C-reactive protein (mg/L) 16.76 ± 9.09 10.2 ± 4.59 18.25 ± 9.36 13.25 ± 5.8 15.44 ± 9.18 8.17 ± 2.32
There is no signiﬁcant difference between male and female patients with BD in the different groups.
Table 6 Correlations between serum homocysteine levels and patients’ characteristics in different groups.
Characteristic Total BD patients (n= 27) BD with eye involvement (n= 12) BD without eye involvement (n= 15)
R P R P R P
Age (years) 0.32 0.10 0.33 0.30 0.03 0.92
Disease duration (years) 0.16 0.41 0.34 0.29 0.01 0.97
C-reactive protein (mg/L) 0.26 0.18 0.29 0.37 0.17 0.55
There are no signiﬁcant correlations between serum homocysteine levels and patients’ characteristics in the different groups.
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become blind [22].
In the current study, higher levels of homocysteine in
Egyptian BD patients were found compared to healthy con-
trols. This is in concordance with several reports on Tunisian,
Turkish and Iranian patients with BD [21,27–34]. In contrast,
other studies found that homocysteine levels in patients with
BD were not elevated [18,26].
The etiology of elevated serum homocysteine is multifacto-
rial. Homocysteine is a metabolite of methionine and can be
converted back to methionine or to cysteine via remethylation
or transsulfuration. The enzyme methylenetetrahydrofolate
reductase (MTHFR) is a pivotal enzyme in homocysteine
metabolism. The genetically determined thermolabile variant
of MTHFR which exerts less enzymatic activity has received
considerable attention. However, most reported studies fail
to demonstrate correlation between homozygosity for thermo-
labile MTHFR and retinal vascular disease [11]. These con-
trasting reports of the relation between TT genotype and
total homocysteine (TH) levels may be related to the age of
the patients studied. Genetic determinants of TH may be more
important in younger patients with premature vascular disease,
whereas nutritional factors may be more important in older
patients [35]. The most important nutritional factors include
the vitamins folate, B6 and B12 and excessive intake of methi-
onine rich proteins [14]. Therapy with folic acid, vitamin B6
and Vitamin B12 has been shown to lower homocysteine levels
and may prevent venous occlusive disease in patients with
hyperhomocysteinemia [15].
In our BD patients, serum homocysteine levels were signif-
icantly higher (P< 0.001) in BD patients with eye involve-
ment compared to those without eye involvement and
healthy controls. They were also higher (P< 0.001) in patients
without eye involvement compared to healthy controls. These
results are in agreement with other studies [10], and are contra-
dictory with others [19,26,35]. The causes of these different
study outcomes are not clear. The different sample sizes,
different disease durations or study patients under treatmentthat might affect outcomes could have contributed. In
addition, the question whether hyperhomocysteinemia
depends on the inﬂammation or not remains unanswered
[10].
The exact mechanism by which hyperhomocysteinemia
causes vascular disease and/or thrombosis is not known. How-
ever, there are two widely accepted hypotheses. According to
the ﬁrst, hyperhomocysteinaemia has deleterious effects on
endothelial cells, causing endothelial cell damage, smooth mus-
cle cell proliferation and increased oxidative stress [36]. In vitro
studies are in favor of this hypothesis. In vitro endothelial cell
cultures showed that homocysteine interfered with vasomotor
regulatory and endothelial anticoagulant functions of vascular
endothelial cells. Vessels from monkeys with moderate hype-
rhomocysteinaemia exhibited increased platelet mediated vaso-
constriction, impaired endothelium dependent vasodilatation
and decreased thrombomodulin dependent activation of
protein C [37].
According to the second hypothesis, homocysteine medi-
ated vascular disease/thrombosis occurs via interference with
coagulation mechanisms. Homocysteine inhibits the expres-
sion and activation of thrombomodulin, which is a cofactor
for protein C activation [37]. Homocysteine also suppresses
the anticoagulant action of antithrombin III [38].
In this study, statistically signiﬁcant differences in the levels
of CRP were found between patients with BD and healthy con-
trols. Similar results were reported by Kartal Durmazlar et al.
[10]. However, no signiﬁcant differences in CRP levels were
found between BD patients with and without eye involvement.
Several laboratory markers correlate in varying degrees with
activity of BD, such as CRP, interleukins 6 and 8, C9,
neuropteran and erythrocyte sedimentation rate. Of these,
CRP correlates well with signs such as erythema nodosum,
acute thrombophlebitis, and acute arthritis [38]. However,
the association of CRP with mucocutaneous, ocular, or central
nervous system activities is weaker [39].
In the present study, no sex difference in homocysteine
levels was shown in our patients with BD. This was the same
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contrast, other studies reported signiﬁcantly higher levels of
homocysteine in male patients with BD which might explain
the higher incidence of thrombosis in men with BD [11,21,35].
In our study, homocysteine levels were not signiﬁcantly cor-
related with age, disease duration and CRP levels either in total
BD patients or BD patients with or without eye involvement. In
contrast, Cahill et al. reported that increasing age is a known
risk factor that elevates homocysteine levels [11].
Our study has two shortcomings. The ﬁrst one was the lack
of evaluation of disease activity because there is no clinically
acceptable scoring system. The second one is that we measured
serum homocysteine level only once for each patient because of
ﬁnancial problems. Further studies are needed to collect the
samples at least twice in three-month intervals for more
accuracy.
In conclusion, we suggest that chronic inﬂammation may
lead to hyperhomocysteinemia, which, in turn, may contribute
to vasculopathic complications of BD including uveitis and
retinal vascular disease. Assessment of homocysteine may be
important in the investigation and management of patients
with BD, especially those with ocular disease.
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